TGFB1 and cancer: Conversely, dual pharmacologic targeting of TGF-β and AURKA pathways efficiently reverses chemoresistance and impairs tumor progression through SNAI1 down-regulation, inhibition of cancer cell plasticity, and selective targeting of ALDH1high cells (Fig. 8d).